Overactive Bladder

U.S. FDA approves treatment for overactive bladder

Published in Medical Letter on the CDC and FDA, December 26th, 2004

Yamanouchi Pharmaceutical Co., Ltd. announced that it received approval from the U.S. Food and Drug Administration (FDA) for the treatment of overactive bladder with symptoms of urgency, frequency and urge incontinence for Vesicare (generic name is solifenacin succinate).

Once-daily Vesicareis a global product of Yamanouchi, and this approval follows the one obtained in Europe where the product was launched in August.

Yamanouchi is constructing a marketing system of its own in the U.S. Vesicare will be marketed by its wholly owned US subsidiary, Yamanouchi Pharma America, Inc (YPA) as the first product Yamanouchi will independently market in the U.S....

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2004-12-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry